dph-2 Antibody

What are the recommended applications for DPH2 antibodies in experimental settings?

DPH2 antibodies can be effectively employed in multiple experimental techniques including immunohistochemistry (IHC), quantitative real-time PCR (qRT-PCR), Western blotting, and immunofluorescence. Based on published research methodologies, DPH2 antibodies work effectively for detecting protein expression in tissue samples through IHC, as demonstrated in prostate cancer studies . Additionally, they are valuable for protein localization studies using immunofluorescence and for quantifying expression levels via Western blotting. When paired with gene expression analysis (qRT-PCR), researchers can generate comprehensive insights into both transcriptional and translational DPH2 regulation.

What controls should be included when using DPH2 antibodies?

When using DPH2 antibodies, researchers should include:

• Positive tissue controls: Tissues known to express DPH2, such as prostate adenocarcinoma samples, which have been confirmed to express high DPH2 levels .

• Negative controls: Normal adjacent tissues that express low DPH2 levels, or antibody diluent without primary antibody.

• Isotype controls: Corresponding to the DPH2 antibody's isotype to rule out non-specific binding.

• siRNA validation controls: Cells with DPH2 knockdown to confirm antibody specificity when possible.

• Loading controls: For Western blotting, include housekeeping proteins like GAPDH or β-actin to normalize protein loading.

The research demonstrates that DPH2 expression levels differ significantly between cancer and normal tissues, making proper controls essential for accurate interpretation .

What is the relationship between DPH2 and other diphthamide synthesis proteins?

DPH2 functions within a network of diphthamide biosynthesis proteins, with correlations to several related genes as shown in the following data table:

This correlation data suggests that when investigating DPH2 using antibody-based methods, researchers should consider potential co-expression with these related proteins, particularly EEF2 and DPH5, which show the strongest correlations .

How do I optimize DPH2 antibody staining for different tumor microenvironments?

Optimizing DPH2 antibody staining across diverse tumor microenvironments requires consideration of microenvironmental variables that affect antibody performance. Research has shown significant correlations between DPH2 expression and tumor microenvironment (TME) scores across 33 cancer types . For optimal staining:

• Antigen retrieval optimization: Different tissue types may require adjusted pH (citrate buffer pH 6.0 vs. EDTA pH 9.0) and heating times based on tissue fixation and processing.

• TME-specific protocol adjustments: In PRAD, DPH2 expression significantly correlates with TMEscore, CD8_T_effector, and Immune_Checkpoint markers . For tissues with extensive immune infiltrates, additional blocking steps may be necessary to reduce background.

• Signal amplification considerations: Tissues with lower DPH2 expression may benefit from signal amplification systems (e.g., tyramide signal amplification).

• Multiplex optimization: When co-staining DPH2 with immune markers (especially follicular helper T cells, M0 macrophages, or CD4 memory T cells), carefully select antibody combinations to avoid cross-reactivity, as DPH2 shows strong correlations with these immune cell populations .

• Validation across microenvironments: Compare staining patterns between hypoxic regions, inflammatory zones, and necrotic areas, as DPH2 has demonstrated associations with hypoxia and cell death pathways .

What methodological approaches help resolve contradictory DPH2 expression data between different experimental techniques?

When facing contradictory DPH2 expression data between different techniques, implement the following methodological approaches:

• Antibody validation hierarchy: Establish a validation sequence beginning with Western blot verification of antibody specificity, followed by IHC with positive and negative controls, and supported by orthogonal methods like RNA-seq or qRT-PCR for gene expression.

• Isoform-specific detection: Consider designing experiments to differentiate potential DPH2 isoforms, as variant-specific expression may explain discrepancies.

• Subcellular localization analysis: Use fractionation techniques followed by Western blotting to determine if discrepancies arise from differential subcellular localization of DPH2, particularly since research indicates DPH2 may function in multiple cellular compartments .

• Quantification standardization: Implement standardized quantification protocols across techniques - for IHC, use digital pathology tools with algorithms that account for staining intensity and percentage of positive cells, as exemplified in prostate cancer studies where DPH2 expression correlated significantly with Gleason scores .

• Cross-platform normalization: When comparing results between platforms, apply appropriate normalization methods and statistical approaches for integrating heterogeneous data types.

How can DPH2 antibodies be effectively used to investigate tumor-immune interactions?

Investigating tumor-immune interactions using DPH2 antibodies requires specialized methodological approaches:

What experimental design best addresses the relationship between DPH2 expression and therapy resistance?

To investigate DPH2's role in therapy resistance, implement the following experimental design:

• Patient-derived xenograft models: Establish PDX models from treatment-naive and resistant tumors, then assess DPH2 expression via IHC and Western blotting before and after treatment exposure. This approach is supported by findings that elevated DPH2 expression links to resistance against multiple anticancer medications .

• Isogenic cell line development: Create isogenic cell lines with modulated DPH2 expression through:

  • CRISPR/Cas9 knockout

  • shRNA knockdown

  • Overexpression systems

  Analyze these models for drug sensitivity changes across different therapeutic classes. The study confirms that DPH2 knockdown inhibited prostate cancer cell proliferation, invasion, and migration .

• Time-course experiments: Design longitudinal studies with sequential sampling during treatment to track DPH2 expression changes in response to therapy pressure.

• Pathway analysis validation: Since GSEA and GSVA revealed significant associations between DPH2 levels and oncogenic/immune-related pathways , design experiments to validate these pathway connections using:

  • Pathway inhibitors in combination with DPH2 modulation

  • Phosphorylation state analysis of key pathway components

  • Transcriptional reporter assays for pathway activity

• Resistance mechanism deconvolution: Differentiate between intrinsic and acquired resistance by comparing baseline and post-treatment DPH2 levels alongside mechanistic studies of:

  • Apoptotic pathway integrity

  • DNA damage response

  • Drug efflux activity

  • Metabolic adaptations

What protocols yield optimal results for DPH2 immunohistochemistry in FFPE tissues?

For optimal DPH2 immunohistochemistry in FFPE tissues, follow this validated protocol derived from successful prostate cancer studies :

• Tissue preparation:

  • Section FFPE blocks at 4-5 μm thickness

  • Mount on positively charged slides

  • Dry sections overnight at 37°C

• Deparaffinization and rehydration:

  • Xylene: 3 changes of 5 minutes each

  • 100% ethanol: 2 changes of 3 minutes each

  • 95%, 80%, 70% ethanol: 3 minutes each

  • Distilled water rinse

• Antigen retrieval:

  • Heat-induced epitope retrieval using citrate buffer (pH 6.0)

  • Pressure cooker method: 121°C for 3 minutes or

  • Microwave method: 95-98°C for 15-20 minutes

  • Cool to room temperature (20 minutes)

• Blocking and antibody incubation:

  • Block endogenous peroxidase: 3% H₂O₂ for 10 minutes

  • Protein block: 5% normal goat serum for 30 minutes

  • Primary DPH2 antibody: Diluted 1:100-1:200, incubate overnight at 4°C

  • Secondary antibody: HRP-conjugated, 30 minutes at room temperature

• Detection and counterstaining:

  • DAB substrate: 5-10 minutes (monitor microscopically)

  • Counterstain: Harris hematoxylin for 30 seconds

  • Bluing agent: 0.2% ammonia water

  • Dehydrate through graded alcohols and clear in xylene

  • Mount with permanent mounting medium

• Controls and validation:

  • Include PRAD tissue sections known to express high DPH2 levels as positive controls

  • Include adjacent normal prostate tissue as negative/low expression controls

This protocol has successfully distinguished DPH2 expression patterns associated with Gleason scores in prostate cancer .

How should DPH2 expression data be analyzed in relation to clinical parameters?

When analyzing DPH2 expression in relation to clinical parameters, implement this methodological framework based on published approaches :

• Expression categorization:

  • Divide samples into "high" and "low" DPH2 expression groups based on:

    • Median expression value

    • Optimal cutoff determined by ROC curve analysis

    • X-tile software for outcome-based cutpoint determination

• Statistical approach:

  • For continuous variables: Use Student's t-test (two groups) or ANOVA (multiple groups)

  • For categorical variables: Apply Chi-square or Fisher's exact test

  • For survival analysis: Implement Kaplan-Meier method with log-rank tests and Cox proportional hazard models

• Multivariate modeling:

  • Include standard prognostic factors alongside DPH2 expression

  • For PRAD specifically, include PSA, Gleason score, T-stage, N-stage, and M-stage

  • Report hazard ratios with 95% confidence intervals

• Correlation analysis:

  • Use Pearson correlation to assess relationships between DPH2 and:

    • Immune cell infiltration scores

    • Cell death-related genes

    • Tumor microenvironment metrics

• Clinical parameter focus:

  • Based on published findings, particularly focus on correlations with:

    • Gleason score (significant correlation demonstrated for PRAD)

    • Disease stage

    • Treatment response

    • Recurrence patterns

The following data table illustrates the significant association between DPH2 expression and clinical parameters in prostate cancer:

What is the recommended methodology for quantifying DPH2 protein expression levels?

For reliable quantification of DPH2 protein expression, implement this comprehensive methodology derived from successful research approaches :

• Western blot quantification:

  • Protein extraction: Use RIPA buffer with protease/phosphatase inhibitors

  • Loading control: Normalize to GAPDH, β-actin, or α-tubulin

  • Densitometry: Apply ImageJ software with background subtraction

  • Technical replicates: Minimum of three independent experiments

  • Data normalization: Express as fold-change relative to control samples

• IHC scoring systems:

  • H-score method: Intensity (0-3) × percentage of positive cells (0-100%), yielding scores of 0-300

  • Allred score: Intensity score (0-3) + proportion score (0-5), yielding scores of 0-8

  • Digital pathology: Employ automated image analysis with algorithms that account for:

    • DAB staining intensity

    • Percentage of positive cells

    • Subcellular localization patterns

• qRT-PCR for mRNA expression:

  • Reference genes: Use multiple stable reference genes (e.g., GAPDH, ACTB, 18S rRNA)

  • Data analysis: Apply 2^(-ΔΔCt) method with appropriate normalization

  • Validation: Confirm key findings with protein-level quantification

• Immunofluorescence quantification:

  • Image acquisition: Standardized exposure settings across all samples

  • Signal quantification: Measure mean fluorescence intensity (MFI)

  • Subcellular analysis: Quantify nuclear vs. cytoplasmic distribution

  • Co-localization metrics: When performing dual staining with binding partners

• Multi-omics integration:

  • Correlate protein expression with:

    • mRNA levels from qRT-PCR or RNA-seq

    • Methylation status of the DPH2 gene

    • Functional endpoints (proliferation, invasion, etc.)

This quantification methodology has successfully distinguished meaningful differences in DPH2 expression between cancer and normal tissues, and among different Gleason score groups in prostate cancer .

What novel applications of DPH2 antibodies are emerging in cancer research?

Several innovative applications of DPH2 antibodies are emerging in cancer research, expanding beyond traditional detection methods:

• Liquid biopsy development:

  • Application of DPH2 antibodies for circulating tumor cell (CTC) capture and identification

  • Development of exosome-based detection systems using DPH2 antibodies for cancer diagnostics

  • Integration into multiplexed CTC characterization panels focusing on therapy resistance biomarkers

• Therapeutic targeting strategies:

  • Antibody-drug conjugate (ADC) development targeting DPH2 in cancer cells

  • CAR-T cell engineering using DPH2 as a target antigen for solid tumors with high DPH2 expression

  • Exploration of DPH2-targeted immunotoxins for selective cancer cell elimination

• Advanced imaging applications:

  • In vivo cancer imaging using radiolabeled or fluorescently tagged DPH2 antibodies

  • Intraoperative optical imaging for surgical guidance in tumor resection

  • Photoacoustic imaging with DPH2-targeted contrast agents

• Functional pathway analysis:

  • ChIP-seq applications to identify potential DPH2 interactions with chromatin

  • Proximity-ligation assays to map DPH2 protein interactions in the tumor microenvironment

  • CRISPR-Cas9 screens combined with DPH2 antibody-based readouts to identify synthetic lethal interactions

• Therapy response monitoring:

  • Development of companion diagnostic assays for therapies affecting pathways linked to DPH2

  • Sequential biopsy analysis with DPH2 antibodies to track treatment response

  • Integration into immune monitoring panels for immunotherapy response assessment

These applications are supported by research findings that DPH2 influences multiple cancer-related pathways, including immune signaling, cell death mechanisms, and therapy resistance .

How can cross-reactivity issues with DPH2 antibodies be addressed in multi-protein analysis?

When encountering cross-reactivity issues with DPH2 antibodies in multi-protein analyses, implement these methodological solutions:

• Antibody validation hierarchy:

  • Western blot specificity confirmation using recombinant DPH2 protein and tissue lysates

  • Knockout/knockdown validation using DPH2-depleted samples (as validated in the PRAD knockdown studies )

  • Peptide competition assays to confirm binding specificity

• Multi-protein panel optimization:

  • Sequential antibody titration to determine minimal effective concentrations

  • Test multiple antibody clones targeting different DPH2 epitopes

  • Implement stringent blocking protocols with:

    • 5% BSA or normal serum from the secondary antibody species

    • Commercial protein-free blockers

    • Mouse/human protein co-block for tissue applications

• Technical approach modification:

  • For co-immunoprecipitation: Use pre-clearing steps with protein A/G beads

  • For multiplex IHC: Employ tyramide signal amplification with antibody stripping between rounds

  • For flow cytometry: Implement fluorescence-minus-one (FMO) controls for each antibody

• Data analysis refinement:

  • Apply spectral unmixing algorithms for fluorescence microscopy

  • Use bioinformatic approaches to identify and correct for cross-reactivity signatures

  • Implement machine learning classification of true vs. false positive signals

• Alternative detection strategies:

  • Consider RNA-based detection methods (RNAscope) for specificity

  • Use mass cytometry (CyTOF) which relies on metal-tagged antibodies rather than fluorophores

  • Develop recombinant antibody fragments with enhanced specificity

These approaches are particularly important when studying DPH2 in relation to immune cell infiltration, as the protein shows correlations with multiple immune cell populations across cancer types .

What emerging technologies will enhance the utility of DPH2 antibodies in cancer research?

Several cutting-edge technologies are poised to revolutionize DPH2 antibody applications in cancer research:

• Spatial transcriptomics integration:

  • Combining DPH2 antibody staining with spatial transcriptomics to correlate protein expression with transcriptional profiles at single-cell resolution

  • Development of computational methods to integrate spatial protein and RNA data

  • Creation of spatial atlases mapping DPH2 expression in relation to tumor microenvironment components

• Advanced antibody engineering:

  • Development of recombinant nanobodies against DPH2 for improved tissue penetration

  • Bispecific antibodies targeting DPH2 and immune checkpoint molecules

  • Antibody fragments optimized for intracellular delivery to modulate DPH2 function

• AI-powered image analysis:

  • Deep learning algorithms for automated quantification of DPH2 expression in complex tissue architectures

  • Predictive models correlating DPH2 spatial patterns with clinical outcomes

  • Computer vision approaches for identifying novel DPH2 expression patterns associated with specific tumor phenotypes

• Microfluidic applications:

  • Single-cell protein analysis platforms for DPH2 quantification in rare cell populations

  • Organ-on-chip models incorporating DPH2 antibody-based sensing

  • Droplet-based assays for high-throughput screening of DPH2 modulators

• In vivo applications:

  • Antibody-based biosensors for real-time monitoring of DPH2 expression changes

  • Theranostic approaches combining imaging and therapeutic targeting of DPH2

  • Immuno-PET imaging with radiolabeled DPH2 antibodies for non-invasive tumor assessment